Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring.
Level 5 - mechanism / opinion, no new human data
Narrative review without formal systematic review methodology or meta-analysis
PubMed 32553575 · doi:10.1016/j.jdiacomp.2020.107585
What was done
The authors searched PubMed and the Cochrane Library for studies examining the clinical applications, limitations, and comparisons of hemoglobin A1C, fructosamine, glycated albumin, 1,5-anhydroglucitol, skin autofluorescence, and continuous glucose monitoring.
What was found
No quantitative effect sizes, diagnostic accuracy metrics, or pooled statistics were reported in the abstract. Qualitatively, hemoglobin A1C reflects 3-month glycemic control; fructosamine and glycated albumin reflect mean glucose over 3 weeks; 1,5-anhydroglucitol measures hyperglycemic excursions over days to weeks; and continuous glucose monitors provide real-time feedback and capture glycemic variability, though barriers include cost, patient discomfort, provider inexperience, and medication interference.
Why it matters
This review outlines complementary glycemic assessment tools when A1C is inaccurate or insufficient, clarifying the specific physiological timeframes each alternative marker reflects.
Limits
The abstract does not report the number of included studies, sample sizes, or quantitative data. As a narrative review, it lacks a formal risk-of-bias assessment. Major highlighted limitations include an absence of standardized diagnostic cutoffs and a lack of long-term longitudinal evidence linking alternative markers to diabetic complications across diverse patient cohorts.
Cited by
- supports Hemoglobin A1C reflects an individual's average blood sugar levels over the preceding three months.